Columbia University's economic activity goes far beyond our campuses. Explore our contributions to science, technology, the arts, our city, our nation, and the world, since 1754: https://www.columbia.edu/content/tradition-innovation-and-growth

What is your why? This is mine 🥹

🥰

🙌 proud to be part of this #Dreamteam #PayItForward @conquercancer.bsky.social HSR YIA!!!

Our @swog.org group chair's blog: SWOG at ASCO, 2025 Starting with @drdawnhershman.bsky.social's Karnofsky Science of Oncology Award Lecture in the opening session, the #ASCO25 Annual Meeting will feature some great work by SWOG researchers. www.swog.org/news-events/...

Who From Oncology is Featured in TIME100 Health 2025? @drkarenknudsen.bsky.social @drdawnhershman.bsky.social oncodaily.com/societies/ti... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TIME100 #Health #TIME100Health

At #ASCO25, @drdawnhershman.bsky.social will be honored with the 2025 David A. Karnofsky Memorial Award for her work in advancing cancer outcomes for all patients. #ASCODailyNews has more on her career & accomplishments: brnw.ch/21wSvbq

Thank you @nytimes.com for highlighting the impact of federal funding cuts on research & patient care. We share a common mission to improve the lives and wellbeing of others, and we share common values that everyone deserves the best care and treatment opportunities. www.nytimes.com/2025/03/18/n...

I am profoundly grateful for this extraordinary honor 💗

Incredible accomplishment from our @swog.org 🫁 team. 👏👏👏

So proud of @minasedrakmd for being recognized as a @SusanGKomen rising star 💫-

Better together- very excited about this @swog.org @alliancenctn.org #CTIU collaboration 🤝

The best part of #SABCS24? Lunch with colleagues of course!

Excited to see #PROCTCAE and #GP5 in the inavolisib label! Recurring points in the FDA discussion about needing dose optimization in early drug development to lower doses, maintain efficacy, and improve tolerability. Also comments about needing enrollment of diverse patients. #SABCS24

Super important not to under-treat elderly women - as life expectancy may be quite high!

Thank you all for your advocacy- I would just add - it is not just about measuring pro’s - it’s critically important to mitigate side effects early to help improve tolerance

Such an important topic - so glad #SABCS24 included this in the program. More work needed to figure out how to include #PRO-cTCAE as an endpoint

S2013 and S1501 Reopen for Enrollment with Key Protocol Updates oncodaily.com/insight/200983 @drdawnhershman.bsky.social #Cancer #CancerTreatment #Chemotherapy #SWOG #S2013 #ICIBasedTherapy #ImmuneRelatedAdverseEvents #S1501 #OncoDaily #SWOGNCORPResearchBaseTrials #Oncology

This @swog.org success story is only possible with #NCI federally funded research 🤞

Congrats to Dr. Parminder Singh and Dr. Sonam Puri - recipients of our latest career awards supporting outstanding @swog.org research #SWOGonc cc @moffittnews.bsky.social thehopefoundation.org/blog/general...

Our SWOG Group Chair blog: Modeling Adverse Event Risk Prediction: S2013 and S1501 Are Reopen to Enrollment! Two key trials by the SWOG #NCORP Research Base have reopened after temporary closures. Both trials are prime examples of public-powered research! www.swog.org/news-events/...

#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH

"Because health insurance has become the face of both the rising premiums and the intrusive cost-containment efforts that are largely delegated to them, they have become the primary target of that anger. But it’s not just insurers," Elliott S. Fisher writes: www.statnews.com/2024/12/05/u...

Congratulations @lynn_hershman for making the Art Review Power 100. 👏👏👏 artreview.com/power-100/

The S2312 trial in #mCRPC asks if adding carboplatin to cabazitaxel will significantly improve radiographic PFS in patients whose tumors are aggressive variant #prostatecancer (AVPC-MS) vs those whose tumors are not. PI: Paul Corn, MD, PhD, @mdanderson.bsky.social swog.org/clinical-trials/S2312

That's a wrap! Yesterday marked our final funding deadline of the year. We're busy reviewing, preparing for 2025, and excited for the next big questions we'll help @swog.org members to answer - thank you to our donors who make it all possible! #SWOGonc Upcoming opportunities: tinyurl.com/SWOG2025

Adherence is such big issue and such a challenging problem solve - we found the same thing in breast cancer patients taking endocrine therapy @swog.org study #S1105- pubmed.ncbi.nlm.nih.gov/32369401/ Lots of work needed to improve outcomes in patients who need oral therapies!!

Many patients in the US struggle to afford their prescription drugs. This JAMA Patient Page outlines 7 strategies that patients can use to access medications at reduced cost. https://ja.ma/4g8HcZI

30% of the patients with cancer in our practice endorse food insecurity!! Shocking but true. Thank you #HCWvsHunger #DiagnoseAndTreats for the inspiration and motivation to be part of this effort. 🙏

Just out in CCR from #DART #rarecancers trial: nivo/ipi can be effective in select non-epithelial #ovariancancer (granulosa cell tumor, ORR 25%, 1CR&1PR/8, >4 yrs). "SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer" aacrjournals.org/clincancerre...

👇

Super excited to welcome Jason Zell as the new co-chair of the #SWOG #NCORP prevention committee 🎉 @supportingswog.bsky.social @swog.org

We all know this is happening but seeing the data is mind blowing 🤯

Vaccines work!

If you need a little inspiration this talk is soooo worth watching! ❤️

Very true - but I would not limit to immunotherapy- the financial issues for the multiple expanded indications for expensive oral therapies that are taken for years is a huge issue we need to address as a community- it’s not enough to show something works if the vast majority don’t have access. 🆘

👇

very excited to see @swog.org and @supportingswog doing @bsky.app - 👍

Established in honor of the late SWOG leader Dr. Nicholas J. Vogelzang, the Vogelzang SWOG GU Scholarship supports early stage investigators' travel to 2 SWOG meetings & pairs them with a senior mentor. Applications for 2025 due January 15. Link in our latest email: conta.cc/3B0tI3n